AGMT Registry for Metastatic Colorectal Cancer Patients Receiving Third Line or Later Treatments

What this Trial Is About

Metastatic colorectal cancer mCRC is a serious condition with limited treatment options after multiple therapies. Researchers are gathering detailed information on patients with mCRC who have already had at least two lines of systemic therapy. This registry aims to understand how these patients are treated and how they fare over time, collecting data from multiple cancer centers in Austria to better evaluate treatment patterns and outcomes. The study involves collecting existing medical data from patient charts, including treatment histories, test results, and imaging studies. Tumor tissue samples from deceased patients will be stored in a central biobank, and additional biological samples may be requested for specific research questions. No new diagnostic or treatment procedures are required beyond routine care. Data collection will continue until patient death or loss to follow-up. Participants involvement includes providing consent for their routine medical data to be recorded in the registry. Researchers will monitor overall survival, progression-free survival, response rates, and potential predictive biomarkers over a period of up to 10 years. Patient confidentiality is maintained by assigning unique identifiers, and no extra visits or therapies are needed beyond usual care.

AGMT Metastatic Colorectal Cancer Registry (mCRC) Third Line and Beyond